<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.2minutemedicine.com/feed/</title><link>https://www.2minutemedicine.com/feed/</link><description>Individual feed output.</description><lastBuildDate>Mon, 04 Aug 2025 06:49:12 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>2 Minute Medicine Rewind August 4, 2025</title><link>https://www.2minutemedicine.com/2-minute-medicine-rewind-august-4-2025/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2016/07/Pills_2-300x150.jpg</image_url><description>Initiation of Pregabalin vs Gabapentin and Development of Heart Failure 1. In patients aged 65 to 89 years of age with non-cancer chronic pain, use of...</description><pubDate>Mon, 04 Aug 2025 11:00:35 GMT</pubDate></item><item><title>Social determinants of health associated with development of long COVID</title><link>https://www.2minutemedicine.com/social-determinants-of-health-associated-with-development-of-long-covid/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2019/07/headache-e1738604424946-300x215.jpg</image_url><description>1. In this prospective cohort study, participants with social risk factors at the time of SARS-CoV-2 infection had a higher risk of developing long CO...</description><pubDate>Sun, 03 Aug 2025 11:00:13 GMT</pubDate></item><item><title>Rituximab may not be superior to standard treatment in inducing remission in eosinophilic granulomatosis with polyangiitis</title><link>https://www.2minutemedicine.com/rituximab-may-not-be-superior-to-standard-treatment-in-inducing-remission-in-eosinophilic-granulomatosis-with-polyangiitis/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/12/infusion_edited-e1442764933669-300x150.jpg</image_url><description>1. In this randomized controlled trial, rituximab was not superior to standard treatment in inducing remission in patients with eosinophilic granuloma...</description><pubDate>Sun, 03 Aug 2025 03:00:11 GMT</pubDate></item><item><title>Randomized Phase III trial of Ramucirumab finds benefit for patients with refractory advanced gastric cancer</title><link>https://www.2minutemedicine.com/randomized-phase-iii-trial-of-ramucirumab-finds-benefit-for-patients-with-refractory-advanced-gastric-cancer/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2019/04/Poorly_cohesive_gastric_adenocarcinoma_high_mag-300x150.jpg</image_url><description>1. The addition of ramucirumab to irinotecan in patients with ramucirumab-refractory advanced or recurrent gastric or gastroesophageal cancer (AGC) di...</description><pubDate>Sun, 03 Aug 2025 00:00:43 GMT</pubDate></item><item><title>Increased Serum 25(OH)D levels associated with decreased mortality risk in adult men</title><link>https://www.2minutemedicine.com/increased-serum-25ohd-levels-associated-with-decreased-mortality-risk-in-adult-men/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2017/08/tablets_PD_edited-300x150.jpg</image_url><description>1. Increases in serum 25 (OH) D concentration were nonlinearly associated with decreased all-cause, cardiovascular disease mortality, and cancer morta...</description><pubDate>Sun, 03 Aug 2025 00:00:20 GMT</pubDate></item></channel></rss>